Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Billiontoone, Inc. (BLLN) - What Are Researchers Saying About This Stock?

Billiontoone logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately bullish: Eleven firms collectively rate Billiontoone “Moderate Buy,” with seven buys, three holds and one sell. The average 12-month price target is $126.25, above the reported share price of $104.67.
  • Insiders have been selling shares: Executives sold 249,025 shares worth approximately $27.4 million during the last quarter, including sizable sales by the CEO and a senior vice president. Insiders still own 50.22% of the company.
  • Billiontoone reported solid quarterly results but trades at a high valuation: The company matched consensus earnings at $0.15 per share and generated $109.45 million in revenue, while its stock carried a P/E ratio of 149.53 and a market capitalization of about $4.94 billion.
  • Want to know the moment analysts change their view on Billiontoone? Get MarketBeat All Access for $149 a year and keep that rate for life.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $126.25.

Several research firms have issued reports on BLLN. Zacks Research raised shares of Billiontoone from a "strong sell" rating to a "hold" rating in a research report on Friday, October 2nd. Weiss Ratings downgraded shares of Billiontoone from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, October 8th. BTIG Research reduced their target price on shares of Billiontoone from $142.00 to $130.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Wall Street Zen downgraded shares of Billiontoone from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Canaccord Genuity Group began coverage on Billiontoone in a report on Wednesday, September 2nd. They issued a "buy" rating and a $120.00 price target for the company.

View Our Latest Report on Billiontoone

Insider Activity

In related news, CEO Oguzhan Atay sold 5,150 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $100.23, for a total value of $516,184.50. Following the completion of the transaction, the chief executive officer owned 3,183 shares of the company's stock, valued at $319,032.09. The trade was a 61.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 2,834 shares of the business's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $105.15, for a total value of $297,995.10. Following the completion of the transaction, the senior vice president directly owned 19,385 shares of the company's stock, valued at approximately $2,038,332.75. The trade was a 12.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 249,025 shares of company stock worth $27,387,892. 50.22% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Forum Financial Management LP acquired a new stake in shares of Billiontoone during the third quarter worth $274,000. Toth Financial Advisory Corp grew its stake in Billiontoone by 60.0% during the 3rd quarter. Toth Financial Advisory Corp now owns 800 shares of the company's stock valued at $85,000 after purchasing an additional 300 shares during the last quarter. Family Legacy Financial Solutions LLC purchased a new stake in Billiontoone during the 3rd quarter valued at about $53,000. MCF Advisors LLC increased its holdings in shares of Billiontoone by 330.8% in the second quarter. MCF Advisors LLC now owns 448 shares of the company's stock valued at $54,000 after purchasing an additional 344 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Billiontoone in the second quarter valued at about $29,000.

Billiontoone Trading Up 1.1%

BLLN opened at $104.67 on Thursday. The firm has a market cap of $4.94 billion and a P/E ratio of 149.53. Billiontoone has a 12 month low of $61.96 and a 12 month high of $150.44. The company has a current ratio of 11.69, a quick ratio of 11.31 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $101.30 and a 200 day moving average of $102.28.

Billiontoone (NASDAQ:BLLN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.15. The company had revenue of $109.45 million during the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. As a group, research analysts forecast that Billiontoone will post 0.80 EPS for the current year.

About Billiontoone

(Get Free Report)

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company's technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company's products include prenatal diagnostic and screening solutions marketed under the UNITY brand.

Featured Articles

Analyst Recommendations for Billiontoone (NASDAQ:BLLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Billiontoone Right Now?

Before you consider Billiontoone, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Billiontoone wasn't on the list.

While Billiontoone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines